Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Procter & Gamble Health's Enterprise Value is ₹99,134 Mil.
Procter & Gamble Health's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil. Therefore, Procter & Gamble Health's EV-to-FCF for today is .
The historical rank and industry rank for Procter & Gamble Health's EV-to-FCF or its related term are showing as below:
BOM:500126'
s EV-to-FCF Range Over the Past 10 Years
Min: 0 Med: 0 Max: 53.1
Current: 53.1
During the past 13 years, the highest EV-to-FCF of Procter & Gamble Health was 53.10. The lowest was 0.00. And the median was 0.00.
BOM:500126's EV-to-FCF is ranked worse than 75.22% of 569
companies
in the Drug Manufacturers industry
Industry Median: 21.6
vs BOM:500126: 53.10
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Procter & Gamble Health (BOM:500126) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Procter & Gamble Health's PE Ratio (TTM) for today is calculated as:
Procter & Gamble Health's share price for today is ₹6087.90.
Procter & Gamble Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹197.140.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Procter & Gamble Health's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Procter & Gamble Health EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Procter & Gamble Health's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Procter & Gamble Health's EV-to-FCF falls into.
Procter & Gamble Health's current Enterprise Value is ₹99,134 Mil.
Procter & Gamble Health's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Is Procter & Gamble Health (BOM:500126) Overvalued in 2026?
Based on GuruFocus' analysis, Procter & Gamble Health stock appears to be undervalued.
The current stock price of ₹6,087.90 is trading 0.6% below its estimated GF Value™ of ₹6,124.41.
GuruFocus considers Procter & Gamble Health to be Fairly Valued.
Key valuation signals for BOM:500126:
EV-to-FCF:
GF Value™: ₹6,124.41 vs. price of ₹6,087.90 (0.6% below fair value)
No single metric tells the full story. See the BOM:500126 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Procter & Gamble Health Ltd is an India based pharmaceutical company engaged in manufacturing and selling of healthcare products, viz., vitamins, minerals and supplements. Patients are end consumers of the products. The Company's distribution channels (direct & indirect), inter alia, include distributors, health care professionals, pharmacies and chemists. Cosome, Evion, Neurobion, Nasivion, Polybion, Livogen and Seven Seas are some of the brands of the company. The geographical segments include sales in India and exports.
88GF Score
Get the complete analysis for BOM:500126
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500126 has been successfully added to your 
